TORCH-E3NCT07933679
SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
3 year TME-free survival rate
Timeframe: the proportion of patients who remain alive and have not undergone total mesorectal excision (TME) surgery within three years from the start of treatment.
Secondary (7)
complete response (CR) rate
Organ preservation rate
3 year local recurrence free survival rate
3 year disease free survival rate
3 year overall survival rate
Show 2 moreShow less
3 year Quality of Life
Grade 3-4 adverse effects rate
Arms and interventions
SCRT plus immunochemotherapy groupExperimental
Patients will receive SCRT (25Gy/5Fx, SCRT), followed by 4 cycles of CAPOX and PD-1 antibody, finally receive the TEM or TME surgery or adopt WW option.
LCRT plus chemotherapy groupOther
Patients will receive LCRT (50Gy/25Fx,LCRT, concurrent capecitabine), followed by 2 cycles of CAPOX, finally receive the TEM or TME surgery or adopt WW option.
Radiation: Short-course radiotherapy, Long-course radiation
Drugs: PD-1 antibody (Sintilimab), Oxaliplatin, Capecitabine
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China